News
One million signatures needed to call upon World Health Organisation
The 1 Mission 1 Million - Getting to the Heart of Stroke initiative is launching a petition to call upon the World Health Organisation, its member states and health authorities worldwide to recognise atrial fibrillation as a risk...
News
Biomarker predicts response to cancer treatment
VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery could be an important step towards personalized medicine...
News
FDA approves generic versions of blood thinner Plavix
The U.S. Food and Drug Administration approved generic versions of the blood thinning drug Plavix, which helps reduce the risk of heart attack and stroke by making it less likely that platelets in the blood will clump and...
News
Amgen’s BiTEĀ® antibody blinatumomab achieved high rate of complete response
Amgen announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia...
News
In drug-approval race, US FDA ahead of Canada, Europe
The U.S. Food and Drug Administration (FDA) generally approves drug therapies faster and earlier than its counterparts in Canada and Europe, according to a new study by Yale School of Medicine researchers. The study counters perceptions that the...
News
Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on DiabetesĀ® to China and India
The Bristol-Myers Squibb Foundation today announced the expansion of its Together on DiabetesĀ® initiative to China and India, pledging $15 million over five years to help these developing nations with rapidly growing numbers of type 2 diabetes patients....
News
Serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis
Ā Recently announced results from two-year CATT (Comparison of Age-related macular degeneration Treatment Trials) adds to the growing body of evidence, including CATT 1-year data and two retrospective database analyses, suggesting serious safety concerns associated with the use of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















